# A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

> **NCT05923073** · PHASE3 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Guselkumab

## Key facts

- **NCT ID:** NCT05923073
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2027-10-27
- **Final completion:** 2028-07-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923073, "A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-09-18 from https://api.ai-analytics.org/clinical/NCT05923073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*